U.S. markets close in 4 hours 46 minutes
  • S&P 500

    3,663.48
    +1.03 (+0.03%)
     
  • Dow 30

    29,823.95
    +0.03 (+0.00%)
     
  • Nasdaq

    12,331.15
    -23.95 (-0.19%)
     
  • Russell 2000

    1,828.56
    -7.49 (-0.41%)
     
  • Crude Oil

    45.20
    +0.65 (+1.46%)
     
  • Gold

    1,830.30
    +11.40 (+0.63%)
     
  • Silver

    24.08
    -0.01 (-0.06%)
     
  • EUR/USD

    1.2089
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    0.9490
    +0.0150 (+1.61%)
     
  • GBP/USD

    1.3333
    -0.0090 (-0.67%)
     
  • USD/JPY

    104.5600
    +0.2440 (+0.23%)
     
  • BTC-USD

    18,808.86
    -185.04 (-0.97%)
     
  • CMC Crypto 200

    368.41
    +3.50 (+0.96%)
     
  • FTSE 100

    6,456.49
    +71.76 (+1.12%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Here's What You Should Know About Coloplast A/S's (CPH:COLO B) 2.0% Dividend Yield

Simply Wall St
·4 min read

Today we'll take a closer look at Coloplast A/S (CPH:COLO B) from a dividend investor's perspective. Owning a strong business and reinvesting the dividends is widely seen as an attractive way of growing your wealth. Yet sometimes, investors buy a popular dividend stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations.

A 2.0% yield is nothing to get excited about, but investors probably think the long payment history suggests Coloplast has some staying power. Some simple analysis can reduce the risk of holding Coloplast for its dividend, and we'll focus on the most important aspects below.

Explore this interactive chart for our latest analysis on Coloplast!

CPSE:COLO B Historical Dividend Yield, March 17th 2020
CPSE:COLO B Historical Dividend Yield, March 17th 2020

Payout ratios

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Comparing dividend payments to a company's net profit after tax is a simple way of reality-checking whether a dividend is sustainable. Coloplast paid out 64% of its profit as dividends, over the trailing twelve month period. This is a fairly normal payout ratio among most businesses. It allows a higher dividend to be paid to shareholders, but does limit the capital retained in the business - which could be good or bad.

In addition to comparing dividends against profits, we should inspect whether the company generated enough cash to pay its dividend. Coloplast paid out 67% of its cash flow as dividends last year, which is within a reasonable range for the average corporation. It's positive to see that Coloplast's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.

Consider getting our latest analysis on Coloplast's financial position here.

Dividend Volatility

From the perspective of an income investor who wants to earn dividends for many years, there is not much point buying a stock if its dividend is regularly cut or is not reliable. Coloplast has been paying dividends for a long time, but for the purpose of this analysis, we only examine the past 10 years of payments. The dividend has been stable over the past 10 years, which is great. We think this could suggest some resilience to the business and its dividends. During the past ten-year period, the first annual payment was ø1.40 in 2010, compared to ø17.00 last year. This works out to be a compound annual growth rate (CAGR) of approximately 28% a year over that time.

With rapid dividend growth and no notable cuts to the dividend over a lengthy period of time, we think this company has a lot going for it.

Dividend Growth Potential

While dividend payments have been relatively reliable, it would also be nice if earnings per share (EPS) were growing, as this is essential to maintaining the dividend's purchasing power over the long term. Strong earnings per share (EPS) growth might encourage our interest in the company despite fluctuating dividends, which is why it's great to see Coloplast has grown its earnings per share at 11% per annum over the past five years. Coloplast's earnings per share have grown rapidly in recent years, although more than half of its profits are being paid out as dividends, which makes us wonder if the company has a limited number of reinvestment opportunities in its business.

Conclusion

Dividend investors should always want to know if a) a company's dividends are affordable, b) if there is a track record of consistent payments, and c) if the dividend is capable of growing. Coloplast's is paying out more than half its income as dividends, but at least the dividend is covered by both reported earnings and cashflow. We like that it has been delivering solid improvement in its earnings per share, and relatively consistent dividend payments. Coloplast has a number of positive attributes, but it falls slightly short of our (admittedly high) standards. Were there evidence of a strong moat or an attractive valuation, it could still be well worth a look.

Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For instance, we've picked out 1 warning sign for Coloplast that investors should take into consideration.

If you are a dividend investor, you might also want to look at our curated list of dividend stocks yielding above 3%.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.